About Aytu BioPharma, Inc.
https://aytubio.comAytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally.
CEO
Joshua R. Disbrow
Compensation Summary
(Year 2025)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-01-06 | Reverse | 1:20 |
| 2020-12-09 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 3 of 15
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
NANTAHALA CAPITAL MANAGEMENT, LLC
Shares:1.09M
Value:$2.99M
STONEPINE CAPITAL MANAGEMENT, LLC
Shares:891.86K
Value:$2.45M
AWM INVESTMENT COMPANY, INC.
Shares:619.57K
Value:$1.7M
Summary
Showing Top 3 of 36
About Aytu BioPharma, Inc.
https://aytubio.comAytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $13.89M ▼ | $10.69M ▼ | $1.97M ▲ | 14.15% ▲ | $-0.08 ▲ | $3.28M ▲ |
| Q4-2025 | $15.13M ▼ | $17.88M ▲ | $-19.82M ▼ | -130.94% ▼ | $-2.92 ▼ | $-17.42M ▼ |
| Q3-2025 | $18.45M ▲ | $10.38M ▼ | $3.99M ▲ | 21.65% ▲ | $0.65 ▲ | $6.04M ▲ |
| Q2-2025 | $16.22M ▼ | $12.48M ▼ | $788K ▼ | 4.86% ▼ | $0.02 ▼ | $2.63M ▼ |
| Q1-2025 | $16.57M | $12.91M | $1.47M | 8.89% | $0.2 | $3.92M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $32.63M ▲ | $124.99M ▲ | $101.82M ▼ | $23.17M ▲ |
| Q4-2025 | $30.95M ▲ | $124.18M ▼ | $105.21M ▲ | $18.97M ▼ |
| Q3-2025 | $18.17M ▼ | $124.2M ▲ | $89.3M ▲ | $34.9M ▲ |
| Q2-2025 | $20.4M ▲ | $116.23M ▲ | $85.46M ▼ | $30.77M ▲ |
| Q1-2025 | $20.11M | $115.83M | $86M | $29.83M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $1.97M ▲ | $-618K ▼ | $0 ▲ | $2.3M ▼ | $1.68M ▼ | $-618K ▼ |
| Q4-2025 | $-19.88M ▼ | $2.8M ▲ | $-3.02M ▼ | $12.99M ▲ | $12.78M ▲ | $2.79M ▲ |
| Q3-2025 | $3.99M ▲ | $-6.46M ▼ | $-69K ▼ | $4.3M ▲ | $-2.23M ▼ | $-6.52M ▼ |
| Q2-2025 | $788K ▼ | $2.9M ▲ | $145K ▼ | $-2.76M ▼ | $290K ▲ | $2.9M ▲ |
| Q1-2025 | $1.47M | $-1.19M | $381K | $911K | $102K | $-1.33M |
Revenue by Products
| Product | Q1-2024 | Q2-2024 | Q3-2024 | Q4-2024 |
|---|---|---|---|---|
 Consumer Health | $0 ▲ | $0 ▲ | $0 ▲ | $10.00M ▲ |
 Other | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Pediatric | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q3-2022 | Q4-2022 | Q1-2023 | Q4-2023 |
|---|---|---|---|---|
 NonUS | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 UNITED STATES | $0 ▲ | $30.00M ▲ | $30.00M ▲ | $80.00M ▲ |
 US | $20.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
CEO
Joshua R. Disbrow
Compensation Summary
(Year 2025)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-01-06 | Reverse | 1:20 |
| 2020-12-09 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 3 of 15
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
NANTAHALA CAPITAL MANAGEMENT, LLC
Shares:1.09M
Value:$2.99M
STONEPINE CAPITAL MANAGEMENT, LLC
Shares:891.86K
Value:$2.45M
AWM INVESTMENT COMPANY, INC.
Shares:619.57K
Value:$1.7M
Summary
Showing Top 3 of 36